Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha
Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha
复制标题
STAT4 变异与接受聚乙二醇化干扰素-α 治疗的 HBeAg 阳性患者的慢性 HBV 感染治愈相关
DOI：
10.1016/j.cgh.2019.04.044
复制
发表时间：
2020-01-01
影响因子：
12.6
通讯作者：
Jiang, De-Ke
中科院分区：
文献类型：
--
作者：
Chen, Haitao;Sun, Jian;Jiang, De-Ke
背景与目的：STAT4 （rs7574865）变异与慢性感染患者接受干扰素α (IFNA)治疗时血清向乙型肝炎e抗原（HBeAg）转化和乙型肝炎病毒（HBV） DNA水平降低有关。我们评估了rs7574865、HB表面抗原（HBsAg， HBV感染功能性治愈的标记物）丢失以及hbeag阳性的慢性HBV感染患者对聚乙二醇化IFNA （PegIFN）或核苷类似物（NUCs）治疗的反应之间的关系。方法：我们对4项4期多中心随机对照试验中的1823例慢性HBV感染hbeag阳性患者（954例接受PegIFN治疗，869例接受NUCs治疗）进行了回顾性分析。采用Cochran-Armitage趋势检验评价rs7574865基因型与联合应答（CR，定义为HBeAg血清转化和HBV DNA水平）的相关性
BACKGROUND & AIMS: Variants in STAT4 (rs7574865) have been associated with seroconversion to hepatitis B e antigen (HBeAg) and reduction in levels of hepatitis B virus (HBV) DNA in patients with chronic infection treated with interferon alpha (IFNA). We evaluated the associations among rs7574865, loss of HB surface antigen (HBsAg, a marker of functional cure of HBV infection), and response to treatment with pegylated IFNA (PegIFN) or nucleos(t)ide analogues (NUCs) in HBeAg-positive patients with chronic HBV infection.METHODS: We performed a retrospective analysis of 1823 HBeAg-positive patients with chronic HBV infection (954 patients treated with PegIFN and 869 patients treated with NUCs) included in 4 phase-4 multicenter randomized controlled trials. The Cochran-Armitage trend test was used to evaluate the association of rs7574865 genotype with combined response (CR, defined as HBeAg seroconversion and HBV DNA level